Cytosorb Therapy in Cardiac Surgery - a Retrospective Study of Hemoadsorption in Patients With Endocarditis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 249
- 试验地点
- 1
- 主要终点
- In-Hospital mortality
研究概览
简要总结
Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with endocarditis undergoing cardiac surgery with cardio-pulmonary bypass circuit
排除标准
- •denial of consent for data use
结局指标
主要结局
In-Hospital mortality
时间窗: during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
In-Hospital mortality (number of deaths) of patients with endocarditis undergoing cardiac surgery and intra-operative CytoSorb haemoadsorption
次要结局
- time in intensive care unit (days)(during hospital stay for cardiac surgery from admission until discharge (approximately 15 days))
- In-Hospital time (days)(hospital stay for cardiac surgery from admission until discharge (approximately 15 days))